- IN₹213.68bn
- IN₹183.24bn
- IN₹25.20bn
Annual cashflow statement for Pfizer, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7,729 | 8,240 | 7,461 | 10,161 | 9,757 |
| Depreciation | |||||
| Non-Cash Items | -383 | -2,368 | -1,516 | -3,177 | -1,206 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,825 | -3,371 | -3,999 | -994 | 547 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 6,671 | 3,557 | 2,568 | 6,598 | 9,676 |
| Capital Expenditures | -153 | -650 | -189 | -282 | -252 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -5,597 | 289 | 726 | -432 | -5,364 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -5,750 | -361 | 537 | -713 | -5,617 |
| Financing Cash Flow Items | -7.8 | -134 | -107 | -77.8 | -85 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,805 | -3,458 | -2,351 | -2,053 | -7,983 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -885 | -262 | 754 | 3,831 | -3,924 |